Moreover, recent studies in other tumour types showed that GLS inhibition also sensitizes cancer cells to proteasome inhibitors due to the induction of ER stress and apoptosis [137], and to EGFR-targeted monoclonal antibodies by triggering apoptosis [138]. The gene discussed is GLS; the disease is neoplasm.